<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811927</url>
  </required_header>
  <id_info>
    <org_study_id>C1210</org_study_id>
    <nct_id>NCT01811927</nct_id>
  </id_info>
  <brief_title>The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent</brief_title>
  <acronym>BIOHELIX-II</acronym>
  <official_title>The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent (BIOHELIX-II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to the assess the clinical performance of the BIOTRONIK&#xD;
      PRO-Kinetic Energy stent in subjects with atherosclerotic disease of native coronary&#xD;
      arteries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent late lumen loss</measure>
    <time_frame>9-months post procedure</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PRO-Kinetic Energy Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRO-Kinetic Energy Stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PRO-Kinetic Energy Stent</intervention_name>
    <description>Bare-metal stent</description>
    <arm_group_label>PRO-Kinetic Energy Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; or = 18 years&#xD;
&#xD;
          -  Willingness to comply with study follow-up requirements&#xD;
&#xD;
          -  Candidate for a PCI procedure&#xD;
&#xD;
          -  Candidate for coronary artery bypass graft surgery&#xD;
&#xD;
          -  Documented evidence of stable or unstable angina pectoris or positive functional&#xD;
             ischemia study (e.g. exercise treadmill test, thallium stress test, SPECT, stress&#xD;
             echocardiogram or cardiac CT)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  De novo or restenotic lesion in a native coronary artery; restenotic lesions must have&#xD;
             been previously treated with only standard PTCA (treatment must be &gt; 12 months prior&#xD;
             to the index procedure)&#xD;
&#xD;
          -  Target lesion must be in a major coronary artery (target vessel). The target vessel&#xD;
             includes the entire territory of the left anterior descending artery, left circumflex&#xD;
             artery or right coronary artery and any major side branch of the artery.&#xD;
&#xD;
          -  A maximum of one target lesion and one non-target lesion may be treated per subject.&#xD;
             The lesions must be located in separate coronary arteries, with treatment of the&#xD;
             non-target lesion occurring first using commercially available therapy (with exception&#xD;
             of brachytherapy).&#xD;
&#xD;
          -  Lesions may be one solid lesion or a series of multiple, smaller lesions to be treated&#xD;
             as one lesion&#xD;
&#xD;
          -  Target lesion must be treatable with a single investigational stent; an additional&#xD;
             stent may be used when treating a vessel dissection or another similar intra-procedure&#xD;
             complication (use of investigational stent preferred)&#xD;
&#xD;
          -  Angiographic evidence of ≥ 50% and &lt; 100% stenosis (by operator visual estimate) with&#xD;
             a TIMI flow &gt; 1&#xD;
&#xD;
          -  Target lesion length of ≤ 31 mm by operator visual estimate&#xD;
&#xD;
          -  Target vessel reference diameter of 2.25 mm to 4.0 mm by operator visual estimate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline LVEF of &lt; 30%; LVEF may be measured and assessed by standard-of-care&#xD;
             echocardiography procedures within 90 days of the index procedure or by a left&#xD;
             ventriculogram prior to the index procedure (operator visual assessment)&#xD;
&#xD;
          -  PCI in any vessel 30 days prior to the index procedure or planned for within 30 days&#xD;
             after the index procedure&#xD;
&#xD;
          -  Stroke or transient ischemic attack within the last 6 months prior to enrollment&#xD;
&#xD;
          -  Intolerance to contrast agents that cannot be medically managed and/or intolerance to&#xD;
             antiplatelet, anticoagulant or thrombolytic medications&#xD;
&#xD;
          -  Refusal of blood transfusions&#xD;
&#xD;
          -  Any other medical condition, that in the opinion of the investigator, poses an&#xD;
             unacceptable risk for implant of a stent according to the study indications&#xD;
&#xD;
          -  Pregnant, planning to become pregnant or nursing during the course of the study. Women&#xD;
             of child-bearing potential must have a negative blood pregnancy (beta hCG) test.&#xD;
             Female subjects who are surgically sterile or post-menopausal are exempt from having a&#xD;
             pregnancy test.&#xD;
&#xD;
          -  Known allergy to L-605 CoCr alloy (cobalt, chromium, tungsten and nickel) or amorphous&#xD;
             silicon carbide&#xD;
&#xD;
          -  Life expectancy of less than one year&#xD;
&#xD;
          -  Participation in any other clinical investigational device or drug study. Subjects may&#xD;
             be concurrently enrolled in a post-market study, as long as the post-market study&#xD;
             device, drug or protocol does not interfere with the investigational treatment or&#xD;
             protocol of this study.&#xD;
&#xD;
          -  Documented diagnosis of an acute MI within 72 hours of the index procedure and an&#xD;
             elevation of Troponin or CKMB above the URL (CKMB measurement is not required if CK is&#xD;
             normal) at the time of the index procedure (99th percentile of the individual&#xD;
             investigative site's normal reference population)&#xD;
&#xD;
             - For subjects with stable angina and elevated Troponin, CKMB &lt;99% URL is required&#xD;
&#xD;
          -  ECG changes consistent with an acute MI within 72 hours of the index procedure. ECG&#xD;
             changes consistent with an acute MI include:&#xD;
&#xD;
               -  &gt; 1 mm ST segment elevation or depression in consecutive leads&#xD;
&#xD;
               -  New LBBB&#xD;
&#xD;
               -  Development of pathological Q-waves in two contiguous leads of the ECG&#xD;
&#xD;
          -  Acute coronary syndrome with baseline Troponin &gt; 99% URL&#xD;
&#xD;
          -  INR ≥ 1.6&#xD;
&#xD;
          -  Concomitant renal failure with serum creatinine level &gt; 2.5 mg/dL&#xD;
&#xD;
          -  Unresolved neutropenia (white blood cell count &lt; 3,000 / SL), thrombocytopenia&#xD;
             (platelet count &lt; 100,000 / SL) or thrombocytosis (platelet count &gt; 700,000 / SL)&#xD;
&#xD;
          -  Unprotected left main CAD (&gt; 50% diameter stenosis by operator visual estimate)&#xD;
&#xD;
          -  Target vessel has been treated with any PCI procedure (e.g. PTCA, stent, cutting&#xD;
             balloon, atherectomy, etc.) within 12 months prior to the index procedure&#xD;
&#xD;
          -  Target lesion has been treated with a stent, cutting balloon or atherectomy any time&#xD;
             prior to the index procedure or has been treated with PTCA within 12 months prior to&#xD;
             the index procedure&#xD;
&#xD;
          -  Target vessel treated with brachytherapy anytime prior to index procedure&#xD;
&#xD;
          -  Planned PCI in the target vessel within 9 months after the index procedure&#xD;
&#xD;
          -  Target vessel has a non-target lesion with a &gt; 50% stenosis that requires treatment&#xD;
             during the index procedure&#xD;
&#xD;
          -  Lesions preventing distal perfusion (TIMI flow 0 and 1) prior to wire crossing&#xD;
&#xD;
          -  Target lesion is in the left main coronary artery or within 2 mm of the origin of the&#xD;
             left anterior descending artery or left circumflex artery by operator visual estimate&#xD;
&#xD;
          -  Target lesion is located within a saphenous vein graft or arterial graft&#xD;
&#xD;
          -  Target lesion involves a bifurcation - lesion is located in a major coronary artery&#xD;
             and involves a side branch with a diameter &gt; 2 mm (by operator visual estimate)&#xD;
&#xD;
          -  Presence of a complication following pre-dilatation of target lesion&#xD;
&#xD;
          -  Presence of a complication following treatment of a non-target lesion (if applicable)&#xD;
&#xD;
          -  Presence of a target vessel/lesion that has excessive tortuousity/angulation or is&#xD;
             severely calcified preventing complete inflation of an angioplasty balloon&#xD;
&#xD;
          -  Angiographic evidence of thrombus within the target lesion&#xD;
&#xD;
          -  Target lesion is located within an aneurysm or associated with an aneurysm in the&#xD;
             vessel segment either proximal or distal to the target lesion&#xD;
&#xD;
          -  Use of cutting balloons, atherectomy or ablative devices immediately prior to&#xD;
             investigational stent placement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Kaiser, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2013</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

